SEC Form 4 · accession 0001477932-17-004609
Citius Pharmaceuticals, Inc. · CTXR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carol Webb
Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 19, 2017 · 9:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506251
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $3.45 | Sep 15, 2017 | A | 10,000 | A | — | Sep 13, 2027 | Common Stock | 10,000 | 10,000 | D |
| Options to Purchase Common StockF2 | $0.015 | holding | — | — | — | — | Mar 17, 2024 | Common Stock | 12,071 | 12,071 | D |
| Options to Purchase Common StockF3 | $12.00 | holding | — | — | — | — | Jun 23, 2026 | Common Stock | 13,334 | 13,334 | D |
Explanation of responses
- F1The options vest in full on the first anniversary of the vesting commencement date, September 13, 2018.
- F2The option vested in 1/3 increments over a three year period with the first installment vesting on March 17, 2015.
- F3The options vested in full on the first anniversary of the date of grant.
Remarks
All numbers reflect a 1-for-15 reverse stock split on June 9, 2017.